A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

Summary

The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.

Timeline

Start

2023-06-29

Primary completion

2026-04-06

Completion

2026-04-06

Publications

• Moore-Ramdin L, van Eeghen A, Stevens J, Takhar P, Meitzler S, Fladrowski C, Rozenberg M, Amin S. Co-Creation of the EpiCom Clinical Trial: Bringing the Tuberous Sclerosis Complex Patient Community, Healthcare Professionals, and the Pharmaceutical Industry Together. Patient. 2026 Jul 11. doi: 10.1007/s40271-026-00830-5. Online ahead of print.

Drugs

Indications